List of Excipients in Branded Drug EVOMELA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Acrotech Biopharma LLC	EVOMELA	melphalan	68152-109	BETADEX
Acrotech Biopharma Inc	EVOMELA	melphalan	72893-001	BETADEX SULFOBUTYL ETHER SODIUM

EVOMELA Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

EVOMELA is a ready-to-use commercial formulation of melphalan hydrochloride that uses sulfobutyl ether beta-cyclodextrin sodium, commonly known as SBECD or Captisol, to address melphalan's poor aqueous solubility. The formulation replaces propylene glycol-based delivery approaches with a lyophilized, reconstituted injectable product. Its principal commercial opportunities are differentiated excipient supply, formulation licensing, hospital pharmacy economics, improved handling, and follow-on products that preserve the SBECD-based solubilization platform.

What is EVOMELA and how does its formulation work?

EVOMELA is melphalan hydrochloride for injection, supplied as a 50 mg lyophilized vial. The product is marketed in the United States by Melphalan Development LLC, an affiliate of Acrotech Biopharma. It is approved for use as conditioning treatment before hematopoietic progenitor cell transplantation in multiple myeloma and for palliative treatment of patients with multiple myeloma who are not candidates for oral therapy or intravenous conventional melphalan therapy.[1]

The formulation contains:

Component	Function
Melphalan hydrochloride	Active pharmaceutical ingredient
Sulfobutyl ether beta-cyclodextrin sodium	Solubilizer and formulation-enabling excipient
Povidone K12	Bulking, stabilizing, and cake-formation aid
Sodium citrate	Buffering and pH-control agent
Sterile water for injection	Reconstitution diluent, supplied separately

EVOMELA is reconstituted before administration and then diluted for intravenous infusion. The product label identifies a 50 mg vial and specifies storage, reconstitution, dilution, and administration requirements.[1]

Why is SBECD important in EVOMELA?

Melphalan has limited water solubility and is chemically unstable in some aqueous environments. Cyclodextrin complexation improves apparent solubility by creating an inclusion complex around hydrophobic portions of the drug molecule. SBECD is an anionic, chemically modified beta-cyclodextrin with an established history in injectable products.

The excipient strategy has four commercial objectives:

1. Enable a stable lyophilized dosage form.
2. Avoid reliance on propylene glycol as the principal solubilizing vehicle.
3. Support rapid preparation in a hospital pharmacy.
4. Create a differentiated formulation that can be protected independently of melphalan's underlying chemical composition.

The formulation does not eliminate the need for controlled handling. Melphalan remains a cytotoxic alkylating agent, and the product requires appropriate pharmacy and infusion precautions.

What excipients protect EVOMELA's product performance?

The highest-value excipient in EVOMELA is SBECD. Povidone and sodium citrate support the dosage form but are less likely to provide the principal commercial differentiation.

SBECD and Captisol

SBECD is widely associated with Ligand Pharmaceuticals' Captisol platform. Captisol is a sulfobutyl ether beta-cyclodextrin product used to improve the solubility and stability of poorly soluble active ingredients. Its use in EVOMELA links the commercial product to a specialized excipient supply chain rather than to a commodity formulation system.[2]

Potential performance benefits include:

• Higher apparent melphalan solubility.
• Reduced dependence on organic cosolvents.
• Compatibility with lyophilized injectable manufacturing.
• Improved flexibility in reconstitution and dilution.
• Potentially better handling characteristics than conventional melphalan injection products.

The commercial value of SBECD depends on the complete formulation and process, not only on the excipient's presence. A competing product would need to demonstrate equivalent solubility, chemical stability, sterility, cake quality, reconstitution time, container compatibility, and clinical performance.

Povidone K12

Povidone K12 is a low-molecular-weight povidone grade used in pharmaceutical formulations. In a lyophilized injectable, it can contribute to cake structure, reduce precipitation risk, and support physical stability. It is generally less differentiated than SBECD because multiple suppliers and grades may be available.

The key development issue is grade substitution. A manufacturer seeking a second source would need to assess:

• Molecular-weight distribution.
• Peroxide and impurity profile.
• Bioburden and endotoxin controls.
• Impact on reconstitution.
• Interaction with melphalan and SBECD.
• Lyophilized cake appearance and collapse temperature.

Sodium citrate

Sodium citrate provides buffering capacity and helps control formulation pH. Melphalan stability is sensitive to formulation conditions, so the citrate concentration and final pH are important process parameters. Citrate is commercially available from multiple pharmaceutical excipient suppliers and is unlikely to be the primary barrier to entry.

Its commercial relevance is greater in combination with the other excipients. Changing the buffer can alter degradation, reconstitution, osmolality, and infusion compatibility.

What formulation patents protect EVOMELA?

EVOMELA's competitive protection is likely to depend more heavily on formulation and regulatory exclusivity than on composition-of-matter protection for melphalan. Melphalan is an older active ingredient whose basic chemical and therapeutic patents have expired.

Publicly available product information identifies EVOMELA's formulation as a proprietary, lyophilized melphalan presentation using SBECD. The relevant intellectual-property categories are:

IP category	Relevance to EVOMELA
Melphalan composition of matter	Expired or commercially exhausted for modern US competition
SBECD-containing formulation	Potentially important for solubility and stability
Lyophilization process	May protect cycle parameters and product quality
Reconstitution and dilution process	May support method claims or labeling differentiation
Container-closure system	May protect compatibility and moisture control
Treatment method	May cover particular conditioning or myeloma-use regimens
Manufacturing process	May create barriers where product quality depends on narrow process controls

A definitive patent-by-patent conclusion requires a current USPTO, FDA Orange Book, and litigation-docket review. The FDA Orange Book should be checked for listed patents and regulatory exclusivity associated with the specific EVOMELA drug-product listing.[3]

What is the Orange Book status of EVOMELA?

EVOMELA is an approved small-molecule injectable product and should be evaluated through the Orange Book framework rather than the biologic-biosimilar pathway. The commercial questions are whether patents are listed against the reference product, whether a generic applicant can file an abbreviated new drug application, and whether a Paragraph IV certification would be required.

The key Orange Book issues are:

• Listed patents covering the drug product or method of use.
• Patent expiration and pediatric-extension status.
• Whether any listed patent is eligible for a Paragraph IV challenge.
• Whether the product has unexpired exclusivity separate from patents.
• Whether a generic applicant can design around the SBECD formulation.

EVOMELA does not have biosimilar exposure because melphalan is a chemically synthesized small molecule. The principal follow-on risk is generic injectable competition.

When does EVOMELA lose exclusivity?

EVOMELA's market exclusivity has several layers:

1. Regulatory exclusivity tied to the original approval or any later qualified supplement.
2. Listed formulation or method-of-use patents.
3. Manufacturing know-how and product-quality controls.
4. Commercial barriers created by hospital adoption and supply reliability.

The product was approved by the FDA in December 2016.[4] Any five-year new chemical entity exclusivity associated with the original approval would have expired in 2021. That does not determine the end of all EVOMELA protection because later formulation patents, listed patents, or granted pediatric exclusivity could extend practical market protection.

Generic entry scenarios

Scenario	Likely effect
Generic copies the SBECD formulation	Direct substitution risk, subject to patent and ANDA approval
Generic uses a different solubilizer	Potential design-around, but requires new formulation development
Generic uses propylene glycol	Possible technical alternative, but may face handling, stability, or labeling disadvantages
Generic launches after Paragraph IV litigation	Entry depends on litigation outcome or settlement terms
Authorized generic or licensed competitor	Faster commercial entry with reduced formulation risk
Hospital compounding substitution	Limited substitute because sterile cytotoxic preparation remains regulated

A non-SBECD generic may have an easier patent position but a harder development program. The applicant would need to establish pharmaceutical equivalence, bioequivalence where applicable, injectable product quality, sterility, stability, and labeling compatibility. For parenteral products, the FDA may place substantial weight on formulation sameness and inactive-ingredient justification.

What Paragraph IV challenges and litigation affect EVOMELA?

A Paragraph IV challenge would target any unexpired Orange Book-listed patent. The highest-probability targets would be formulation claims covering the combination of melphalan with SBECD, specified excipient ranges, lyophilized dosage forms, or reconstitution characteristics.

A challenger could pursue one of three strategies:

1. Formulation sameness

The applicant uses SBECD, povidone, citrate, and substantially equivalent quantities. This approach may reduce development risk but creates the greatest exposure to formulation patents.

2. Excipient design-around

The applicant replaces SBECD with another cyclodextrin, cosolvent, surfactant, or complexing agent. This may reduce patent exposure but introduces technical and regulatory risk.

3. Process and presentation design-around

The applicant retains the same general excipient concept but changes the dosage form, vial strength, lyophilization process, or reconstitution system. This strategy may avoid narrow claims but can create comparability and usability challenges.

No litigation conclusion should be drawn from the existence of a patent alone. The relevant analysis requires claim construction, prosecution history, Orange Book listing data, ANDA filing dates, and any settlement agreement. Public litigation records should be reviewed through PACER and the FDA patent-certification framework before an investment or licensing decision.

What commercial opportunities exist for EVOMELA excipients?

Can suppliers license SBECD technology?

The most attractive opportunity is a supply or licensing arrangement involving pharmaceutical-grade SBECD. A supplier could offer:

• Primary or secondary SBECD supply.
• Regional manufacturing rights.
• Capacity reservations.
• Quality-by-design support.
• Regulatory documentation for excipient qualification.
• Supply-chain resilience for oncology injectables.

Because SBECD is a specialized excipient, qualification can be more difficult than switching between commodity buffers or bulking agents. Any supplier agreement should address change control, audit rights, impurity specifications, continuity of supply, and rights to support alternate manufacturing sites.

Can a competitor develop a non-SBECD melphalan formulation?

Yes, but the opportunity is technically demanding. Candidate strategies include:

• Alternative cyclodextrins.
• Polymeric solubilizers.
• Surfactant systems.
• Cosolvent systems.
• Amorphous solid dispersions for reconstituted injection.
• Concentrated liquid presentations.
• Ready-to-dilute infusion systems.
• Dual-chamber or closed-system pharmacy devices.

The commercial value of a non-SBECD formulation would depend on a measurable advantage, such as longer in-use stability, faster reconstitution, reduced preparation steps, reduced vial waste, or lower excipient cost.

Can EVOMELA's presentation be improved?

Presentation-level innovation may offer a lower-risk entry point than a new active formulation. Potential products include:

• Smaller or larger vial strengths.
• Ready-to-use bags.
• Closed-system transfer-compatible packaging.
• Automated compounding cartridges.
• Improved reconstitution devices.
• Unit-dose pharmacy kits.
• Shelf-life extensions.
• Temperature-tolerant packaging.

These products could generate licensing opportunities even if the core melphalan formulation remains protected.

How strong is EVOMELA's patent estate?

EVOMELA's patent estate is likely strongest where formulation claims are narrow but technically difficult to design around. SBECD is a recognizable formulation differentiator, but the excipient itself is a known technology. Patent strength therefore depends on claim scope.

Stronger claim characteristics

• Claims covering defined melphalan-to-SBECD ratios.
• Specific pH and concentration ranges.
• Stability data tied to the claimed formulation.
• Lyophilized compositions with defined reconstitution performance.
• Claims that cover both composition and manufacturing process.
• Demonstrated superiority over conventional melphalan injection.

Weaker claim characteristics

• Broad claims to melphalan plus a generic solubilizer.
• Claims relying only on the known use of SBECD.
• Claims with broad excipient ranges unsupported by examples.
• Process claims that can be avoided without changing product quality.
• Method-of-use claims that duplicate established melphalan treatment.

Commercial diligence should score the estate across validity, infringement, enforceability, geographic coverage, and freedom to operate. The existence of a US patent does not create equivalent protection in Europe, Japan, Canada, or emerging markets.

How does EVOMELA compare with conventional melphalan injection?

Attribute	EVOMELA	Conventional melphalan injection
Active ingredient	Melphalan hydrochloride	Melphalan hydrochloride
Dosage form	Lyophilized injectable	Injectable presentation
Principal solubilization approach	SBECD-based formulation	Conventional vehicle system
Clinical role	Conditioning and palliative multiple myeloma treatment	Established melphalan uses
Main differentiation	Formulation, handling, and stability profile	Legacy product familiarity
Generic risk	Formulation and injectable-product competition	More mature generic competition
Excipient opportunity	SBECD, lyophilization, packaging, devices	Cost reduction and alternate presentation

EVOMELA's value proposition is not a new mechanism of action. It is a formulation and product-delivery proposition built around an established cytotoxic drug.

What is the revenue exposure and competitive outlook?

EVOMELA revenue is exposed to the relatively mature multiple myeloma and transplant-conditioning markets. Demand is influenced by:

• Number of autologous stem-cell transplants.
• Use of high-dose melphalan conditioning.
• Hospital formulary placement.
• Availability and price of conventional melphalan.
• Generic injectable entry.
• Treatment-center pharmacy economics.
• Supply reliability during oncology-drug shortages.

The product's commercial durability will depend on whether hospitals assign economic value to its preparation, handling, and supply characteristics. A premium price is more defensible when the formulation reduces pharmacy labor, waste, preparation complexity, or product loss.

What geographic coverage matters for EVOMELA?

The United States is the central patent and regulatory market because of FDA approval and Orange Book-based generic competition. Other relevant markets include:

• European Union, where national and centralized regulatory pathways apply.
• Canada, where patent listing and generic procedures differ from the United States.
• Japan, where injectable oncology products may face distinct quality and reimbursement requirements.
• Australia, where generic substitution and patent enforcement follow separate rules.
• China and India, where local manufacturing and price competition can materially affect commercial returns.

SBECD supply, sterile fill-finish capacity, and local registration rights may be more important than patent duration in lower-price markets.

Key Takeaways

• EVOMELA is a lyophilized melphalan hydrochloride injectable that uses SBECD as its principal solubility-enabling excipient.
• The product's commercial differentiation comes from formulation, stability, reconstitution, and handling rather than a new active ingredient.
• SBECD supply and licensing are the most significant excipient-related commercial opportunities.
• Povidone K12 and sodium citrate are important supporting excipients but are less likely to create durable standalone barriers.
• Generic risk is concentrated in injectable formulation competition, Orange Book-listed patents, and Paragraph IV challenges.
• Biosimilar risk does not apply because melphalan is a small-molecule drug.
• Non-SBECD formulations could design around formulation claims but would face substantial development and regulatory requirements.
• Packaging, reconstitution devices, ready-to-use presentations, and sterile manufacturing partnerships may offer additional licensing opportunities.
• Current patent, Orange Book, and litigation records must be reviewed before assigning a definitive expiration date or assessing settlement-based entry timing.

FAQs

Is Captisol the same as SBECD used in EVOMELA?

Captisol is a commercial brand associated with sulfobutyl ether beta-cyclodextrin. The FDA label identifies the excipient by its chemical description, SBECD. Commercial sourcing and licensing rights should be confirmed through the applicable supplier agreement and regulatory documentation.

Does EVOMELA contain propylene glycol?

The EVOMELA label identifies SBECD, povidone K12, and sodium citrate as formulation excipients. Propylene glycol is not identified as the principal solubilizing excipient in the marketed lyophilized formulation.[1]

Can a generic melphalan product avoid EVOMELA's patents by using a different excipient?

Potentially, but the alternative product would need to satisfy injectable-drug quality, stability, sterility, reconstitution, labeling, and regulatory requirements. A formulation change may reduce patent exposure while increasing development risk.

Is SBECD supply a manufacturing bottleneck?

It can be a strategic supply constraint because pharmaceutical-grade SBECD is more specialized than citrate or povidone. The commercial risk depends on qualified suppliers, regional capacity, inventory policy, and the sponsor's rights to alternate sources.

Are EVOMELA's excipients suitable for other oncology drugs?

SBECD can support other poorly soluble injectable compounds, but each drug requires independent compatibility, stability, toxicology, container-closure, and regulatory evaluation. EVOMELA's formulation cannot be transferred to another active ingredient without new development work.

References

1. U.S. Food and Drug Administration. (2023). EVOMELA (melphalan hydrochloride) for injection: Prescribing information.
2. Ligand Pharmaceuticals Incorporated. (2024). Captisol sulfobutyl ether beta-cyclodextrin pharmaceutical excipient platform.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2016, December 20). FDA approves EVOMELA for multiple myeloma.